Hyperlipidemias

The supplied material supports genetic causes and broader disturbances in lipid metabolism. It also links hyperlipidemia to metabolic syndrome and to gut microbiota-related metabolites, suggesting that altered host-microbiota interactions can contribute to the condition.

The core biological feature is elevated circulating lipid burden, particularly low-density lipoprotein cholesterol in the evidence base provided. The reviews also describe dysregulation of lipid metabolism, including roles for gut microbiota-derived metabolites such as bile acids, lipopolysaccharide, and short-chain fatty acids, and note FGF21 as a regulator of metabolic homeostasis that can lower dyslipidemia.

Hyperlipidemia is associated with cardiovascular risk and is listed alongside obesity, diabetes, hypertension, smoking, and lack of physical activity as major risk factors for cardiovascular disease. The grounding also supports metabolic syndrome as a context in which hyperlipidemia commonly occurs.

The literature describes lifestyle modification and dietary change as standard management approaches. It also identifies lipid-lowering medications such as statins as conventional therapy, while newer work explores genome editing and gut-microbiota-targeted interventions as emerging treatment modalities.